kin-3248
·Code: KIN-3248
kin-3248: developed by 1 company · 1 clinical trial tracked.
kin-3248 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect kin-3248 to KNTE; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could kin-3248 → KNTE affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| KINNATE BIOPHARMA INC. (KNTE) Solid Tumor, Adult | Phase 1 |
Clinical Trials (1)
A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
Primary endpoint: Part A (dose escalation) - incidence of dose limiting toxicities (DLTs)
Interventionalopen54 targetStarted 2022-03Completion 2024-1021 sites · China, Denmark, South Korea, Spain…Kinnate Biopharma
Frequently asked questions
Who is developing kin-3248?
kin-3248 is being developed by KINNATE BIOPHARMA INC..
How many clinical trials involve kin-3248?
BioSniper tracks 1 clinical trial involving kin-3248.